Search results

Page 1 of 11

Your search for Alzheimer's returned 107 results

Order results by:

Target: GPR3 (Class A Orphans)
Consequences of altering gene expression: implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain.
Consequences of altering gene expression: accumulation of the amyloid-beta peptide in vitro and in an Alzheimer's disease mouse model
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - role: neurons and may be a potential therapeutic target for the treatment of Alzheimer's disease
Target: programmed cell death 1 (CD279) (CD molecules)
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - role: Alzheimer's disease anti-PD1 antibody treatment was used to induce immune checkpoint blockade. The biological
Receptor Immuno Comment: Alzheimer's disease (AD): In mouse models of AD anti-PD-1 antibody treatment was used
Target: presenilin 2 (A22: Presenilin)
Synonym: presenilin 2 (Alzheimer disease 4)
Mutations/pathophysiology - disease: Alzheimer disease 4
Mutations/pathophysiology - disease: Early-onset autosomal dominant Alzheimer disease aka Alzheimer disease 4
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease 4
Ligand: leucomethylthioninium
Comments: Alzheimer's disease (AD) and other tau-opathies. We believe this is the compound being
Clinical use: Alzheimer's Association International Conference in Toronto (July 2016) and reported on the NewScientist website
Mechanism of action: Alzheimer's plaques and filaments respectively. Inhibition of the formation of tau filaments/tangles is one strategy
Ligand: flortaucipir (18F)
Comments: P10636) in Alzheimer's disease brains. Compare with the approved agent, , used to visualise beta-amyloid.
Clinical use: NCT02016560, in cognitively healthy volunteers and patients with mild cognitive impairment and Alzheimer's disease.
Bioactivity comments: Alzheimer's disease patients . Flortaucipir (18F) signal co-localises with beta-amyloid, but does not bind
Ligand: florbetaben
Comments: Alzheimer's disease (AD) . and are the two other PET reagents approved for Abeta detection
Clinical use: Abeta) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) .
Mechanism of action: Alzheimer's disease. The 18F radioactive tracer can then be detected by PET scanning and its accumulation
Target: presenilin 1 (A22: Presenilin)
Mutations/pathophysiology - disease: Alzheimer disease 3
Mutations/pathophysiology - disease: Early-onset autosomal dominant Alzheimer disease aka Alzheimer disease 3
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease 3
Target: C5a1 receptor (Complement peptide receptors)
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - comment: Alzheimer's disease. Inhbition of C5aR, through oral administration of PMX205, in these models reduces
Ligand: AQW051
Comments: Alzheimer's, and Parkinson's diseases. Structure first disclosed at March 2014 ACS meeting. The (3S) version
Clinical use: Alzheimer's, and Parkinson's diseases in clinicaltrials.gov entries , However, none have yet been published
Ligand: flutemetamol
Comments: Alzheimer's disease neurodegeneration. However imaging agents have been granted only narrow approval since they
Clinical use: emitter is used for PET imaging in patients with Alzheimer's disease, and is reviewed in .

1 2 3 4 5 6 7 8 9 10 11

Target search page
Ligand search page